MarketCapExport financials
Xeris Pharmaceuticals (XERS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Xeris Pharmaceuticals XERS
$ 7.59
1.81%
Facebook
X
Telegram
Xeris Pharmaceuticals Financial Ratios 2025-2011 | XERS
Brief overview of Xeris Pharmaceuticals's market valuation
The review covers five available annual periods spanning 2021 to 2025.
The valuation comparison uses P/S 3.31x (median 2.99x), P/B 70.67x (median 6.94x). The current ratio basket stands about 464.4% above the five-year base, increasing sensitivity to weak reports.
Current measures of operating quality are ROE 4%, ROA 0.1%, ROCE 181.9%. Business quality is below comfortable levels on current returns. Better margins or turnover are needed.
On PEG (0.26x), valuation is restrained relative to growth, but one ratio cannot replace cash-flow and risk analysis.
A longer cycle, from 190.2 days to 535.1 days, indicates slower release of cash from operations.
What the ratios show
Xeris Pharmaceuticals's multiples are demanding relative to current business quality. Material improvement is needed to justify them.
Annual Financial Ratios Xeris Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
1746.1 | -11.1 | -5.5 | -1.9 | -1.5 | -2.6 | -1.2 | -3.0 | - | - | - | - | - | - | - |
P/S |
3.3 | 3.0 | 2.1 | 1.6 | 3.8 | 11.5 | 57.1 | 72.9 | - | - | - | - | - | - | - |
EPS |
- | -0.4 | -0.5 | -0.7 | -1.6 | -2.1 | - | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
1.23 B | 887 M | 605 M | 359 M | 330 M | 360 M | 250 M | 224 M | 103 M | 65.5 M | - | - | - | - | - |
EBITDA per Share |
0.16 | -0.22 | -0.31 | -0.59 | -1.44 | -1.78 | -4.65 | -4.9 | - | - | - | - | - | - | - |
EV/EBITDA |
46.8 | -27.4 | -14.2 | -4.5 | -2.6 | -3.5 | -1.6 | -2.8 | - | - | - | - | - | - | - |
PEG |
-26.68 | 0.26 | 0.14 | - | - | -0.05 | -0.34 | 0.03 | - | - | - | - | - | - | - |
P/B |
70.7 | -20.5 | -50.5 | 4.0 | 2.0 | 6.9 | 10.8 | 2.4 | - | - | - | - | - | - | - |
P/CF |
33.8 | -16.4 | -7.3 | -1.8 | -2.0 | -2.9 | -1.5 | -3.1 | - | - | - | - | - | - | - |
ROE % |
4.05 | 185.16 | 917.94 | -209.49 | -128.87 | -269.96 | -869.91 | -79.68 | - | - | - | - | - | - | - |
ROA % |
0.14 | -16.97 | -19.30 | -27.48 | -40.32 | -57.27 | -115.22 | -50.05 | - | - | - | - | - | - | - |
ROCE % |
181.87 | 113.61 | 648.92 | -181.34 | -120.92 | -63.80 | -149.89 | -54.02 | - | - | - | - | - | - | - |
Current Ratio |
1.0 | 0.9 | 1.0 | 1.2 | 1.5 | 5.4 | 3.2 | 11.6 | - | - | - | - | - | - | - |
DSO |
57.2 | 71.5 | 78.0 | 79.9 | 64.2 | 122.8 | 756.1 | 424.8 | - | - | - | - | - | - | - |
DIO |
500.9 | 431.1 | 405.0 | 345.5 | 248.3 | 326.8 | 495.5 | - | - | - | - | - | - | - | - |
DPO |
23.0 | 68.7 | 103.0 | 109.1 | 122.3 | 122.0 | 1275.8 | 7526.0 | - | - | - | - | - | - | - |
Operating Cycle |
558.1 | 502.7 | 483.0 | 425.5 | 312.5 | 449.6 | 1251.6 | 424.8 | - | - | - | - | - | - | - |
Cash Conversion Cycle |
535.1 | 434.0 | 380.0 | 316.4 | 190.2 | 327.7 | -24.2 | -7101.1 | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Xeris Pharmaceuticals
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.18 | 0.01 | - | -0.01 | -0.06 | - | -0.11 | -0.1 | -0.14 | - | -0.09 | -0.14 | -0.12 | - | -0.16 | -0.19 | -0.25 | - | -0.39 | -0.41 | -0.3 | - | -0.35 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
0.03 | 0.05 | 0.06 | 0.05 | -0.02 | - | -0.07 | -0.04 | -0.1 | - | -0.02 | -0.1 | -0.09 | - | -0.12 | -0.12 | -0.21 | - | -0.35 | -0.38 | -0.27 | - | -0.28 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
274.54 | -18.72 | 19.68 | 169.60 | 366.41 | 340.17 | 24.80 | -176.23 | -310.05 | -516.85 | -556.51 | -276.56 | -166.05 | -110.03 | 946.82 | 848.13 | 842.07 | 877.02 | 829.63 | -326.06 | -295.53 | -254.05 | -47.39 | -98.84 | -107.81 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-7.39 | -2.76 | -8.23 | -12.92 | -17.99 | -15.06 | -18.78 | -19.92 | -20.63 | -14.99 | -22.20 | -26.70 | -30.65 | -25.41 | -45.22 | -48.07 | -9.99 | - | -19.81 | - | - | - | -10.05 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-797.29 | -735.35 | -750.67 | 73.55 | 251.98 | 243.18 | 116.06 | -46.60 | -133.23 | -288.44 | -322.56 | -221.03 | -134.03 | -89.85 | 899.92 | 804.37 | 792.24 | 822.39 | 781.68 | -129.66 | -37.71 | - | -40.71 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
1.0 | 1.0 | 1.0 | 0.9 | 0.9 | 0.9 | 0.9 | 0.9 | 1.0 | 1.0 | 1.0 | 1.0 | 1.1 | 1.1 | 1.2 | 1.3 | 1.4 | 1.5 | 1.0 | - | - | 1.3 | 1.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
56.7 | 60.4 | 65.5 | 63.4 | 65.8 | - | 70.3 | 75.8 | 86.0 | - | 71.9 | 73.3 | 84.8 | - | 81.8 | 88.6 | 84.4 | - | 55.9 | - | 38.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
565.8 | 611.4 | 559.1 | 460.1 | 527.3 | - | 295.7 | 491.1 | 609.1 | - | 415.5 | 396.0 | 461.3 | - | 329.7 | 329.7 | 254.5 | - | 201.8 | - | 208.7 | - | 134.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
75.9 | 77.6 | 66.3 | 60.6 | 45.2 | - | 44.5 | 75.5 | 142.6 | - | 131.8 | 142.6 | 142.3 | - | 91.5 | 168.1 | 145.6 | - | 60.8 | - | 77.9 | - | 50.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | 624.6 | 523.4 | 593.1 | - | 366.0 | 566.9 | 695.1 | - | 487.4 | 469.4 | 546.0 | - | 411.4 | 418.3 | 338.9 | - | 257.7 | - | 247.0 | - | 134.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | 558.2 | 462.8 | 547.9 | - | 321.5 | 491.4 | 552.5 | - | 355.6 | 326.8 | 403.8 | - | 320.0 | 250.2 | 193.3 | - | 196.9 | - | 169.1 | - | 84.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Xeris Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |